top of page

The CEO of Corbus on nectin-4 ADCs, integrin biology, and an alternative to GLPs for weight loss

Yuval Cohen describes why he believe his company's nectin-4 ADC has a next generation design, he covers the idea of integrin inhibition for cancer, and describes the oral weight loss pill Corbus will be advancing to the clinic.





Comments


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

bottom of page